

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 November 2018 (01.11.2018)



(10) International Publication Number
WO 2018/197503 A1

(51) International Patent Classification:

C07D 471/18 (2006.01) *A61K 31/4184* (2006.01)
C07D 487/08 (2006.01) *A61K 31/506* (2006.01)
C07D 487/18 (2006.01) *A61K 31/55* (2006.01)

(21) International Application Number:

PCT/EP2018/060489

(22) International Filing Date:

24 April 2018 (24.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17168027.5 25 April 2017 (25.04.2017) EP

(71) Applicants: UCB BIOPHARMA SPRL [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE). SANOFI [FR/FR]; 54 rue la Boétie, 75008 Paris (FR).

(72) Inventors: BROOKINGS, Daniel Christopher; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DE HARO GARCIA, Teresa; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). FORICHER, Yann; 54 rue la Boétie, 75008 Paris (FR). HORSLEY, Helen Tracey; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). HUTCHINGS, Martin Clive; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). JOHNSON, James Andrew; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). MACCOSS, Malcolm; c/o Bohicket Pharma Consulting LLC, 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455 (US). XUAN, Mengyang; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). ZHU, Zhaoning; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: DUCKWORTH, Timothy John; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

(57) Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF α activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

WO 2018/197503 A1